DOCDATA's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing DOCDATA's valuation are provided below:
Market Capitalization
30.9 M
Enterprise Value Revenue
1.9855
There are over fourty-five available fundamental measures for DOCDATA, which can be analyzed over time and compared to other ratios. Investors should ensure to verify all of DOCDATA's latest performance against the performance from 2010 to 2026 to make sure the company is sustainable in the future. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
As of February 6, 2026, Net Loss is expected to decline to about (758.8 K). In addition to that, Net Loss is expected to decline to about (758.8 K).
DOCDATA
Net Income
Investments
Change In Cash
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Total Assets
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Total Liab
Total Current Assets
Net Debt
Common Stock Shares Outstanding
Net Invested Capital
Net Working Capital
Intangible Assets
Other Current Liab
Net Receivables
Capital Stock
Property Plant And Equipment Net
Property Plant And Equipment Gross
Tax Provision
Net Interest Income
Interest Income
Interest Expense
Operating Income
Net Income From Continuing Ops
Ebit
Total Operating Expenses
Income Before Tax
Total Revenue
Gross Profit
Cost Of Revenue
Selling General Administrative
Ebitda
Reconciled Depreciation
Probability Of Bankruptcy
Analyzing DOCDATA's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing DOCDATA's current valuation and future prospects.
Latest DOCDATA's Net Income Growth Pattern
Below is the plot of the Net Income of DOCDATA over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in DOCDATA financial statement analysis. It represents the amount of money remaining after all of DOCDATA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is DOCDATA's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DOCDATA's overall financial position and show how it may be relating to other accounts over time.
It's important to distinguish between DOCDATA's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DOCDATA should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, DOCDATA's market price signifies the transaction level at which participants voluntarily complete trades.
DOCDATA 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to DOCDATA's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of DOCDATA.
0.00
11/08/2025
No Change 0.00
0.0
In 3 months and 1 day
02/06/2026
0.00
If you would invest 0.00 in DOCDATA on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding DOCDATA or generate 0.0% return on investment in DOCDATA over 90 days. DOCDATA is related to or competes with Abbott Laboratories, Advanced Micro, Philip Morris, Amgen, Hong Kong, AP Mller, and FREEPORT MCMORAN. DOCDATA is entity of Germany. It is traded as Stock on BE exchange. More
DOCDATA Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure DOCDATA's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess DOCDATA upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for DOCDATA's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as DOCDATA's standard deviation. In reality, there are many statistical measures that can use DOCDATA historical prices to predict the future DOCDATA's volatility.
DOCDATA retains Efficiency (Sharpe Ratio) of -0.0494, which denotes the company had a -0.0494 % return per unit of risk over the last 3 months. DOCDATA exposes eighteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm DOCDATA's Standard Deviation of 2.17, variance of 4.73, and Market Risk Adjusted Performance of 0.9063 to check the risk estimate we provide. The firm owns a Beta (Systematic Risk) of -0.21, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning DOCDATA are expected to decrease at a much lower rate. During the bear market, DOCDATA is likely to outperform the market. At this point, DOCDATA has a negative expected return of -0.0975%. Please make sure to confirm DOCDATA's standard deviation, information ratio, and the relationship between the coefficient of variation and variance , to decide if DOCDATA performance from the past will be repeated in the future.
Auto-correlation
-0.24
Weak reverse predictability
DOCDATA has weak reverse predictability. Overlapping area represents the amount of predictability between DOCDATA time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of DOCDATA price movement. The serial correlation of -0.24 indicates that over 24.0% of current DOCDATA price fluctuation can be explain by its past prices.
Correlation Coefficient
-0.24
Spearman Rank Test
-0.58
Residual Average
0.0
Price Variance
0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
At present, DOCDATA's Net Interest Income is projected to increase significantly based on the last few years of reporting.
DOCDATA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DOCDATA's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DOCDATA could also be used in its relative valuation, which is a method of valuing DOCDATA by comparing valuation metrics of similar companies.
DOCDATA is currently under evaluation in net income category among its peers.
The Macroaxis Fundamental Analysis modules help investors analyze DOCDATA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DOCDATA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DOCDATA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
DOCDATA financial ratios help investors to determine whether DOCDATA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOCDATA with respect to the benefits of owning DOCDATA security.